View the latest news and SEC filings
Scroll to
Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dual inhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., May 06, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona” or the “Company”), a biopharmaceutical company focused on
Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre ® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a.m. EDT / 2:00 p.m.
LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 and host an investment community conference call
RIPSA interests repurchased Term loan facility increased to $450 million with more favorable terms Access to up to an additional $200 million LONDON and RALEIGH, N.C., March 28, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company
| Date | Form | Filing Group | ||
|---|---|---|---|---|
|
April 18, 2017 |
Registration of depository shares evidenced by American Depository Receipts |
F-6 |
Registration Statements |
|
|
April 18, 2017 |
CORRESP |
CORRESP |
Other |
|
|
April 17, 2017 |
UPLOAD |
UPLOAD |
Other |
|
|
April 3, 2017 |
Registration statement for certain foreign private issuers |
F-1 |
Registration Statements |
|
|
April 3, 2017 |
CORRESP |
CORRESP |
Other |
|
|
March 17, 2017 |
UPLOAD |
UPLOAD |
Other |
|
|
March 3, 2017 |
mendment to a previously filed DRS |
DRS/A |
Registration Statements |
|
|
February 13, 2017 |
A statement of beneficial ownership of common stock by certain persons |
SC 13G |
Other |
|
|
January 30, 2017 |
mendment to a previously filed DRS |
DRS/A |
Registration Statements |
Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.
